Proteomics International公司获得了其PromarkerEndo子宫内膜异位症血液检测产品在澳大利亚的专利受理通知，专利保护期限至2041年3月[1]。该检测方法通过测量血液中特定蛋白质生物标志物来诊断子宫内膜异位症[1]。公司首席执行官David Morris表示："IP Australia对PromarkerEndo专利的受理是一项重大成就，验证了我们创新诊断测试的新颖性和商业潜力。"[1]
Proteomics International已在日本和美国获得该技术专利，并正在加拿大、中国、欧洲、印度、新加坡和韩国申请专利保护[1]。公司于7月与Healius公司签署独家全国分销协议，后者在澳大利亚拥有2000多个患者采样中心[1]。子宫内膜异位症目前影响约1/9的女性，诊断平均需要7年时间[1]。
Proteomics International, an Australian medical technology company, has received patent acceptance notification in Australia for PromarkerEndo, its innovative blood-based diagnostic test for endometriosis [1]. The patent protection extends through March 2041 and covers the company's proprietary method of diagnosing endometriosis by measuring specific protein biomarkers in blood [1].
The company has already secured patents for the technology in Japan and the United States, with patent applications pending in Canada, China, Europe, India, Singapore, and South Korea [1]. Endometriosis affects one in nine women and currently requires an average of seven years for diagnosis [1]. In July, Proteomics International signed an exclusive national distribution agreement with Healius, which operates more than 2,000 patient sampling centers across Australia [1]. CEO David Morris stated that "IP Australia's acceptance of the PromarkerEndo patent is a major achievement, validating the novelty and commercial potential of our innovative diagnostic test" [1].